BioLineRx Ltd. (TLV:BLRX)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
1.400
-0.200 (-12.50%)
Aug 3, 2026, 5:24 PM IDT

BioLineRx Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.41.1828.944.8--
Revenue Growth
-93.72%-95.92%502.92%---
Gross Profit
1.110.9519.681.11--
Operating Income
-10.9-10.29-19.15-42.99-29.16-24.78
Net Income
-7.9-1.18-9.22-60.61-24.95-27.05
Earnings Per Share
-0.00-0.00-0.01-0.06-0.03-0.04
EPS Growth
------

Revenue by Geography

Fiscal YearFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '24 Dec '23
China
-14.964.61
U.s.
1.1813.980.19
Total
1.1828.944.8

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
17.3520.8819.5642.9951.0857.14
Total Debt
9.0710.1515.0411.5912.324.65
Net Cash (Debt)
8.2810.734.5231.438.7652.48
Net Cash Growth
-34.40%137.20%-85.60%-18.98%-26.15%252.17%
Net Cash Per Share
0.000.000.000.030.050.08

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-7.76-8.07-43.87-22.61-26.24-23.57
Capital Expenditures
-0.03-0.03-0.05-0.12-0.13-0.1
Free Cash Flow
-7.79-8.1-43.93-22.72-26.37-23.67
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
79.24%80.51%67.99%23.08%--
Operating Margin
-777.46%-871.78%-66.18%-895.65%--
Pretax Margin
-694.79%-171.69%-31.86%-1262.79%--
Profit Margin
-563.69%-99.58%-31.86%-1262.79%--
FCF Margin
-555.92%-686.36%-151.78%-473.42%--

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-14.4514.4514.4514.4514.45
PS Ratio
8.8811.100.8124.01--